Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” 30 de May de 2025 by Kim, H.-D., Ryu, M.-H., Kang, Y.-K.
